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Cardiovascular Manifestations of Systemic Sclerosis: A Danish
Nationwide Cohort Study
Sheraz A. Butt, MD; Jørgen L. Jeppesen, MD, DSc; Christian Torp-Pedersen, MD, DSc; Flora Sam, MD; Gunnar H. Gislason, MD, PhD;
Søren Jacobsen, MD, DSc; Charlotte Andersson MD, PhD
Background-—Cardiovascular involvement in systemic sclerosis (SSc) comprises a wide range of manifestations with prevalence
and incidence that remain uncertain.
Methods and Results-—In the Danish administrative registries between 1995 and 2015, all patients aged ≥18 years with a first
diagnosis of SSc were matched by age and sex with controls (1:5) from the general population. Prevalence of cardiovascular
diseases at the time of the SSc diagnosis and incidence during follow-up were assessed by in- and outpatient discharge diagnoses.
Conditional logistic and Cox proportional hazards regression models were used respectively to calculate odds ratios for prevalent
cardiovascular diseases and hazard ratios (HRs) for incident diseases associated with SSc. Patients with SSc (n=2778; 76%
women; meanSD age: 5515 years) had more established cardiovascular risk factors than their respective controls at baseline,
including greater prevalence of hypertension (31.2% versus 21.0%, P<0.0001) and treated dyslipidemia (9.8% versus 8.5%, P=0.02).
SSc was associated with an increased relative risk of developing most cardiovascular diseases, including myocardial infarction (HR:
2.08; 95% CI, 1.65–2.64), peripheral vascular disease (HR: 5.73; 95% CI, 4.63–7.09), pulmonary hypertension (HR: 21.18; 95% CI,
14.73–30.45), mitral regurgitation (HR: 4.60; 95% CI, 3.12–6.79), aortic regurgitation (HR: 3.78; 95% CI, 2.55–5.58), aortic
stenosis (HR: 2.99; 95% CI, 2.25–3.97), pericarditis (HR: 8.78; 95% CI, 4.84–15.93), heart failure (HR: 2.86; 95% CI, 2.43–3.37),
atrial fibrillation (HR: 1.75; 95% CI, 1.51–2.04), and venous thromboembolism (HR: 2.10; 95% CI, 1.65–2.67). Additional
adjustment for medications and comorbidities yielded results similar to the main analyses.
Conclusions-—In this nationwide study, SSc was associated with greater risks of distinct cardiovascular diseases for patients than
for matched controls, suggesting a significant disease-related adverse impact across the vascular bed and specific cardiac
structures. ( J Am Heart Assoc. 2019;8:e013405. DOI: 10.1161/JAHA.119.013405.)
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S ystemic sclerosis (SSc; also called scleroderma) is aconnective tissue disease with substantially increased
cardiopulmonary morbidity and mortality.1 Microvascular
impairment is a pathognomonic feature in SSc with manifes-
tations such as Raynaud phenomenon, pulmonary arterial
hypertension, and renal crisis being well characterized.
Several pathways in SSc vasculopathy (eg, endothelial
dysfunction, inflammation, impaired coagulation or fibrinoly-
sis, and oxidative stress) may lead to atherosclerotic mani-
festations.2 Moreover, SSc-related vasculopathy combined
with immune dysregulation and progressive fibrosis (hallmark
features of SSc) are implicated in the pathogenesis of large
vessel disease and specific cardiac dysfunction, but the
clinical impact remains uncertain.3–5
A recent Danish study found SSc to be a significant risk
factor for all-cause cardiovascular disease (defined as a
composite end point including death due to cardiovascular
disease).6 However, few studies have examined the inci-
dence of individual macrovascular manifestations such as
myocardial infarction, stroke, peripheral artery disease, and
venous thromboembolism7–9 and data on the prevalence of
valvular heart disease and arrhythmias in SSc are scarse.10–13
We aimed to investigate the burden of cardiovascular disease
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in a nationwide sample of patients with incident SSc
compared with matched controls. Using the Danish health-
care registers, we specifically estimated the prevalence and
incidence of ischemic manifestations (acute myocardial
infarction, stroke, peripheral vascular disease), arrhythmias
(atrial fibrillation), conduction blocks (atrioventricular and
left bundle-branch block) and hitherto unknown risk of
device implantation (pacemaker or implantable cardioverter-
defibrillator), cardiac valve disease (aortic and mitral steno-
sis and regurgitation), aortic disease (aortic aneurysm and
dissection), and established manifestations including pul-
monary hypertension, heart failure, pericarditis, and venous
thromboembolism in SSc. We hypothesized that patients
with SSc would be at increased risk of cardiac and vascular
manifestations across the whole spectrum of cardiovascular
diseases.
Methods
Data obtained through the nationwide registers in Denmark
can be made available only through research on Danish
servers hosted in highly protected research environments
where researchers can be granted access and permission with
encrypted person identification. Access to raw data can be
gained only through collaboration with the authors or other
Danish institutions that already have been granted access.
Please contact the first author with any questions regarding
data access. Additional methods can be found in Data S1.
Study Design
The study is a nationwide cohort study that included all
patients with a first-time registration of SSc versus age- and
sex-matched controls (1:5) from the Danish healthcare
registries between January 1, 1995, and December 31,
2015. The study was conceived in agreement with the
recommendations for cohort studies by the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE)
initiative.14
Data Sources
For this study we cross-linked the Central Population Registry
(using individual-level data) with the National Patient Registry
and the National Prescription Registry. The Central Population
Registry contains the unique personal identification numbers
of all Danish residents along with information on their birth
date, sex, and vital status. The National Patient Registry
contains information on all in- and out-hospital diagnoses,
registered according to the International Classification of
Diseases (ICD) system, using the Eighth Revision (ICD-8) from
1978 to 1993 and the Tenth Revision (ICD-10) since 1994.
The accuracy and completeness of diagnostic coding in the
National Patient Registry has been evaluated as consistently
high for a variety of chronic comorbidities and cardiovascular
diagnoses,15–18 and we have previously found a positive
predictive value of 94% for the SSc diagnosis in this registry.19
The National Prescription Registry holds information on all
prescription claims since 1995 with all drugs classified
according to the Anatomical Therapeutic Chemical (ATC)
classification system. Because of reimbursement-driven pol-
icy, this registry is considered high quality.20
Study Population
In the National Patient Registry, we identified all first-time
diagnoses of SSc (ICD-10 codes M34, except for M34.2) that
followed outpatient or inpatient visits between 1995 and 2015.
We excluded patients with a prior diagnosis of SSc, defined as
an ICD-10 code ofM34 in 1994 or an ICD-8 code of 734 anytime
between 1978 and 1993. The controls consisted of 5 randomly
selected age- and sex-matched individuals from the Central
Population Registry. An index date was assigned to each control
that corresponded to the date of first registration of SSc for his
or her respective case, in accordance with the principle of
incidence density sampling.21
Outcome Variables and Follow-Up
The primary outcome variables were defined by ICD-8 and
ICD-10 codes, together with procedural codes (obtained via
the National Patient Registry) and medication use (obtained
Clinical Perspective
What Is New?
• This nationwide retrospective cohort (n=2778 individuals
with systemic sclerosis) study spanning 1995–2015 con-
firms and quantifies a wide spectrum of cardiovascular
complications for systemic sclerosis patients compared with
a general-population control group.
• We observed that both well-established manifestations (eg,
pulmonary hypertension) and less evaluated cardiovascular
complications (eg, myocardial infarction, peripheral vascular
disease, aortic and mitral regurgitation) were more preva-
lent at the time of diagnosis and during follow-up among
patients with systemic sclerosis versus controls.
What Are the Clinical Implications?
• The increased prevalence, incidence, and relative risk of
cardiovascular manifestations in systemic sclerosis under-
score a significant adverse impact of systemic sclerosis
across the vascular bed and specific cardiac structures,
warranting increased focus on less recognized complica-
tions.
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via the ATC Classification System coding in the National
Prescription Registry). Table S1 shows the different variables,
different registries, and corresponding diagnosis or proce-
dure/surgical codes for each outcome.
Comorbidity and Medications
Baseline comorbidity comprised prevalent conditions at any
time before study inclusion. Comorbidity included hyperten-
sion, atrial fibrillation, heart failure of any cause, myocardial
infarction, ischemic stroke, aortic aneurism and dissection,
aortic stenosis and regurgitation, mitral stenosis and regurgi-
tation, conduction block (left bundle-branch block and atri-
oventricular block), implantation of pacemaker or implantable
cardioverter-defibrillator, pericarditis, peripheral vascular dis-
ease, pulmonary hypertension, venous thromboembolism,
treated dyslipidemia, and diabetes mellitus. Baseline treatment
was defined by at least 1 prescription dispensed for each
respective drug up to 180 days before the study inclusion date.
The following drugs were included: aspirin, NSAIDs, statins, oral
anticoagulants, antiplatelet therapy, and glucocorticoids.
Statistical Analysis
Continuous variables are presented as meanSD, and cate-
gorical variables are presented as absolute numbers and
percentages. Tests for differences between groups were
performed by the Pearson v2 or Fisher exact test (categorical
data) or by the Student t test (continuous data), as appropriate.
Time at risk was measured from the index date (date of SSc
diagnosis), and individuals were censored at the date of first-
time registration of the specific end point, migration, or death.
Conditional logistic regression models and Cox proportional
hazards regression models were used respectively to calculate
the odds ratios (ORs) for prevalent cardiovascular diseases and
hazard ratios (HRs) for incident diseases associated with SSc.
Separate models were run for each end point. The main models
were adjusted for age and sex. In addition, a multivariable Cox
regression model (including all comorbidities and treatment in
Table 1) was applied to investigate the association of SSc and
outcomes after adjustment for various comorbidities and risk
factors. Two-sided P<0.05 was considered statistically signif-
icant for all analyses. All analyses were performed in SAS v9.4
(SAS Institute).
Ethics
All data were anonymized to the investigators. The study was
approved by the Danish Data Protection Agency (ref. 2007-
58-0015, int. ref. GEH-2014-018, I-suite 02736). Because the
study is retrospective and registry-based using deidentified
data, Danish law does not require ethics approval. The Danish
procedures for safeguarding patient anonymity prohibit the
reporting of outcomes with ≤3 events. The first author had full
access to the data and takes responsibility for its integrity and
for the data analysis.
Results
Study Population
The demographic characteristics and baseline comorbidities
for patients with SSc and matched controls are shown in
Table 1. Baseline Characteristics of SSc Patients and
Controls
Variable
SSc Cases
(n=2778)
Controls
(n=13 890) P Value
Female sex 2114 (76) 10 570 (76)
Age, y, meanSD 5515 5515
Hypertension 867 (31.2) 2915 (21.0) <0.0001
Atrial fibrillation
and atrial flutter
77 (2.8) 189 (1.1) <0.0001
Heart failure 84 (3) 166 (1) <0.0001
Myocardial infarction 86 (3.1) 260 (1.9) <0.0001
Ischemic stroke 69 (1.3) 224 (2.5) <0.0001
Aortic aneurism 9 (0.3) 25 (0.2) 0.1247
Aortic dissection ≤3 ≤3 0.4385
Aortic stenosis 15 (0.5) 35 (0.3) 0.0113
Aortic regurgitation 19 (0.7) 30 (0.2) <0.0001
Mitral stenosis ≤3 ≤3 0.1615
Mitral regurgitation 13 (0.5) 32 (0.2) 0.0276
Conduction block
(left bundle-branch
or atrioventricular block)
15 (0.5) 28 (0.2) 0.0013
Pacemaker/implantable
cardioverter-defibrillator
18 (0.7) 54 (0.4) 0.0572
Pericarditis 28 (1.0) 29 (0.2) <0.0001
Peripheral vascular
disease
121 (4.4) 133 (1.0) <0.0001
Pulmonary hypertension 22 (0.8) 14 (0.1) <0.0001
Venous thromboembolism 93 (3.4) 156 (1.1) <0.0001
Diabetes mellitus 139 (5.0) 585 (4.2) 0.0616
Aspirin 344 (12.4) 1055 (7.6) <0.0001
NSAIDs 752 (27.1) 1733 (12.5) <0.0001
Glucocorticoids 379 (13.6) 352 (2.5) <0.0001
Treated dyslipidemia 273 (9.8) 1177 (8.5) 0.0208
Oral anticoagulant 109 (3.9) 176 (1.3) <0.0001
Antiplatelet therapy 375 (13.5) 1153 (8.3) <0.0001
Data are shown as n (%) except as noted. SSc indicates systemic sclerosis.
DOI: 10.1161/JAHA.119.013405 Journal of the American Heart Association 3
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Table 1. The study population comprised 2778 patients (76%
female) with a diagnosis of SSc and 13 890 controls with an
overall follow-up time of 8.9 years. A total of 722 (26%) and
1.938 (14%) patients died in the SSc and matched cohorts,
respectively, with an age- and sex-adjusted HR for all-cause
mortality of 2.68 (95% CI, 2.43–2.94).
The presence of other autoimmune tissue disorders was
low but higher among patients with SSc than controls (114
[4.1%] versus 97 [0.7%] for rheumatoid arthritis, 41 [1.5%]
versus 8 [0.06%] for systemic lupus erythematosus, and 48
[1.7%] versus 4 [0.03%] for mixed connective tissue disease;
all P <0.0001). Cardiovascular risk factors such as hyperten-
sion (OR: 1.82; 95% CI, 1.66–2.01) and treated dyslipidemia
(OR: 1.21; 95% CI, 1.04–1.40) were more frequent in the SSc
cohort compared with control participants. The prevalence of
most cardiovascular disorders was found to be higher in the
SSc cohort than in the matched population. Very few SSc
patients had either aortic disease (≤9) or mitral stenosis (≤3)
at baseline.
Incidence rates for new-onset cardiovascular manifesta-
tions are presented in Table 2. Table 2 also shows the total
number of events in each cohort in patients with SSc and
controls for all outcomes. SSc patients had higher risks
(Figure) of developing myocardial infarction (HR: 2.08; 95%
CI, 1.65–2.64), ischemic stroke (HR: 1.28; 95% CI, 1.04–
1.58), peripheral vascular disease (HR: 5.73; 95% CI, 4.63–
7.09), atrial fibrillation (HR: 1.75; 95% CI, 1.51–2.04), heart
conduction block (atrioventricular and left bundle-branch;
HR: 1.73; 95% CI, 1.14–2.62), pulmonary hypertension (HR:
21.18; 95% CI, 14.73–30.45), heart failure (HR: 2.86; 95%
CI, 2.43–3.37), pericarditis (HR: 8.78; 95% CI, 4.84–15.93),
mitral regurgitation (HR: 4.60; 95% CI, 3.12–6.79), aortic
regurgitation (HR: 3.78; 95% CI, 2.55–5.58) and stenosis
(HR: 2.99; 95% CI, 2.025–3.97), and venous thromboem-
bolism (HR: 2.10; 95% CI, 1.65–2.67). The proportions of
patients with incident myocardial infarction who were
revascularized within 30 days (either by coronary artery
bypass grafting surgery or percutaneous coronary
Table 2. Incidence of Various Cardiovascular Comorbidities and Conditions During Follow-Up
Variable
SSc Cases (n=2778) Controls (n=13 520)
Incident
Cases
Incidence Rate
Per 100 Person-Years Incident Cases Incidence Rate Per 100 Person-Years
Hypertension 1320 15.21 (14.42–16.06) 5081 6.96 (6.77–7.16)
Atrial fibrillation 235 0.92 (0.81–1.04) 713 0.54 (0.50–0.58)
Heart failure 229 0.92 (0.81–1.05) 451 0.34 (0.31–0.37)
Myocardial infarction 100 0.39 (0.32–0.48) 252 0.19 (0.17–0.22)
Ischemic stroke 112 0.43 (0.36–0.52) 439 0.33 (0.31–0.37)
Aortic aneurism 21 0.08 (0.05–0.12) 74 0.05 (0.04–0.07)
Aortic dissection ≤3 NA 12 0.01 (0.005–0.02)
Aortic stenosis 77 0.29 (0.23–0.36) 133 0.10 (0.08–0.12)
Aortic regurgitation 44 0.16 (0.12–0.22) 58 0.04 (0.03–0.05)
Mitral stenosis 6 0.02 (0.01–0.05) ≤3 NA
Mitral regurgitation 49 0.18 (0.14–0.24) 53 0.04 (0.03–0.05)
Conduction block
(left bundle- branch
or atrioventricular block)
30 0.11 (0.08–0.16) 91 0.07 (0.05–0.08)
Pacemaker or
implantable
cardioverter-defibrillator
48 0.18 (0.13–0.23) 137 0.10 (0.08–0.12)
Pericarditis 30 0.11 (0.08–0.16) 18 0.01 (0.01–0.02)
Peripheral
vascular disease
184 0.75 (0.65–0.87) 182 0.14 (0.12–0.16)
Pulmonary
hypertension
153 0.58 (0.49–0.68) 36 0.02 (0.02–0.04)
Venous
thromboembolism
95 0.37 (0.30–0.46) 232 0.17 (0.15–0.20)
NA indicates not assessed; SSc, systemic sclerosis.
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intervention) were similar for SSc cases and controls (31%
versus 35%; P=0.44).
Further adjustment for medications (aspirin, NSAIDs,
glucocorticoids, statins, oral anticoagulants, and platelet
inhibitors) and comorbidities yielded results similar to the
main analyses (Table S2), except for ischemic stroke (HR:
1.13; 95% CI, 0.90–1.42).
Validation
To increase the likelihood of causality underlying our obser-
vations, we used the 2 known genetic variants associated with
SSc from prior genome-wide association studies, rs3894194
and rs4134466, as instrument variables to look for associa-
tions with various cardiovascular disorders in the UK
Biobank.22,23 Multiple disorders, including myocardial infarc-
tion, heart failure, aneurisms, arrhythmias, and peripheral
vascular disease were associated with the single-nucleotide
polymorphisms at P<0.05 (Table S3). In addition, evidence
suggested a causal association with nonrheumatic mitral
valve disease (P=0.058).
Discussion
In this nationwide cohort study comprising all Danish SSc
patients from 1995 to 2015 and matched controls, we
confirm well-known associations between SSc and pulmonary
hypertension, pericarditis, and atrial fibrillation. In addition,
we show that less evaluated cardiovascular complications
(ischemic manifestations, valvular disease, venous throm-
boembolism) are both more prevalent at the time of SSc
diagnosis and occur at higher incidence rates after diagnosis
in SSc patients compared with matched controls. In contrast
to the established cardiovascular manifestations of SSc (eg,
pericarditis), the increased risks associated with several of the
less well-recognized diseases were moderate. However, given
the overall higher prevalence and incidence rates of the many
cardiovascular manifestations, increased attention to the risk
of cardiovascular diseases in SSc patients is warranted.
Atherosclerotic Cardiovascular Disease
Systemic inflammatory autoimmune diseases are associated
with premature atherosclerosis. Although the degree of overt
systemic inflammation and renal involvement may be less
profound in SSc than in, for example, systemic lupus (which is
well known to be associated with atherosclerosis, especially
in the presence of nephropathy),24,25 we hypothesize that part
of the observed association may be due to inflammation in
SSc.26,27 A few studies of limited size have suggested that
patients with SSc have similar or lower prevalence of
traditional cardiovascular risk factors such as hypertension,
dyslipidemia, and diabetes mellitus compared with con-
trols.7,28,29 In contrast, our study observed higher prevalence
of hypertension, treated dyslipidemia, and diabetes mellitus in
patients with SSc than controls. Similar to our findings,
registries have pointed toward increased prevalence of
coronary heart disease in SSc patients compared with
controls,30 with recent studies showing a 2.0- to 3.5-fold
increased relative risk of myocardial infarction.7,28,31
Peripheral vascular disease in SSc has recently come into
focus with the use of angiography and subclinical markers
such as pulse wave velocity, ankle brachial index, and
systolic/diastolic interarm difference.32–34 Few studies have
been conducted, but a recent case–control study comprising
858 individuals with SSc found incidence rates (7.6/
1000 person-years) and HRs (4.57; 95% CI, 2.99–7.01)
similar to ours.7 Aortic disease (aneurysm or dissection)
involvement has been reported in only a few case reports,35
and our study confirms it being uncommon in SSc. Cerebral
vascular involvement in patients with SSc has been studied
previously by assessing carotid intima media thickness, and
findings have been inconclusive findings,36,37 although higher
prevalence of intracerebral calcifications38 and white matter
hyperintensities39 has been suggested in patients with SSc
compared with age- and sex-matched controls. In contrast to
a few prior smaller studies,40,41 some recent studies have
shown a slightly increased risk of ischemic stroke (HR: 1.44–
2.56) in patients with SSc compared with controls.7,31,42 Our
findings of an increased crude risk of ischemic stroke partially
mirror findings of a disproportionately lower relative risk of
Figure. Forest plot. Odds ratio (prevalent disease) or hazard
ratio (incident disease) for various cardiovascular conditions
associated with systemic sclerosis, adjusted for age and sex.
Relative risks are expressed as odds ratios for prevalent diseases
and hazard ratios for incident diseases. *Defined as atheroscle-
rosis in peripheral artery or aorta.
DOI: 10.1161/JAHA.119.013405 Journal of the American Heart Association 5
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ischemic cerebral disease compared with the risk of ischemic
heart disease and peripheral vascular disease, albeit insignif-
icant in the fully adjusted model.
Arrhythmias and Conduction Defects
Arrhythmias and cardiac conduction defects are common in
SSc, presumably because of myocardial ischemic, fibrotic, and
inflammatory lesions.43 In selected SSc cohorts, electrophys-
iological abnormalities have been reported in 25% to 85% of
patients and transient atrial arrhythmias reported in 20% to
30%.12,44 Our study confirms an increased prevalence (2.8%)
at the time of diagnosis and almost 2-fold increased relative
risk of atrial fibrillation for SSc patients during follow-up; a
similar 2-fold risk of implantation of pacemakers and
cardioverter-defibrillators was found in the SSc cohort.
Pulmonary Hypertension and Heart Failure
Pulmonary hypertension and resulting right-sided heart failure
is a significant cause of morbidity and mortality in SSc.45 In
contrast, echocardiographically diagnosed left ventricular
systolic dysfunction is infrequently seen (5%),46 although
diastolic dysfunction may contribute more to mortality than
recognized previously.47 Of note, subclinical myocardial
abnormalities are detected more often by tissue Doppler or
magnetic resonance imaging than with conventional echocar-
diography, in line with the typically gradual and subtle disease
progression over time.48 The prevalence of pulmonary hyper-
tension is estimated to be 7%,49 and incidence estimates
have been reported to be 1.37 to 1.85/100 person-years,
based on modalities such as echocardiography and right heart
catheterization.50,51 Our register-based prevalence at time of
diagnosis and incidence rate estimates of 0.58/100 person-
years (95% CI, 0.6–0.8) are lower than expected. Because the
manifestation is insidious, our findings could be explained in
part by the study design, the time span applied, and the
modalities required (echocardiography, right heart catheteri-
zation), making it likely that SSc-related pulmonary hyperten-
sion may be underdiagnosed and underreported in the
National Patient Registry. However, the 21-fold increased
relative risk of pulmonary hypertension (HR: 21.18; 95% CI,
14.73–30.45) during follow-up underscores the well-known
association between SSc and pulmonary hypertension.
Pericarditis
Pericardial involvement in SSc was first described in autopsy
studies52 and may occur in 2 patterns.53 Consistent with prior
autopsy studies, pericardial involvement has been character-
ized through modalities like echocardiography10,54 and
magnetic resonance imaging55 as being an indolent chronic
process, often with smaller pericardial effusions that are not
always clinically apparent. However, it can also present as an
acute disorder with symptomatic pericarditis for which larger
effusions are known to be associated with poorer progno-
sis.53,56,57 Literature on the prevalence and risk of symp-
tomatic pericarditis is scarce. We found that overt pericarditis
leading to clinical registration occurred in 1% of SSc patients
at time of diagnosis, with a 6-fold increased relative risk
during follow-up. Nevertheless, the absolute numbers are low,
indicating that clinical symptomatic pericarditis remains a rare
complication.
Cardiac Valve Disease
Cardiac valve disease has not gainedmuch attention even though
early autopsy studies described minor valvular lesions in patients
with SSc.52 A few echocardiographic studies have reported an
association between SSc and, particularly, valvular regurgita-
tion,10,11,58 but the risk of incident valve disease has not been
studied previously. In our study, we found a 3-fold increased
relative risk of aortic stenosis, a 4-fold increased relative risk of
aortic regurgitation, and an almost 5-fold increased relative risk of
mitral regurgitation. The relative risk of mitral stenosis was
similarly found to be increased 10-fold but limited by a small
number of cases and a wide CI. In accordance with a recent
Swedish study,59 our findings illustrate that cardiac valve disease
can develop during the natural history of disease and thus be
regarded as a specific SSc-related complication.
Venous Thromboembolism
Autoimmune disorders are recognized as risk factors for venous
thromboembolism, presumably because of chronic inflamma-
tion and hypercoagulability.60 Prior studies imply an increased
risk of venous thrombosis; for instance, a recent meta-analysis
based on 5 studies, although hampered by high statistical
heterogeneity, reported a pooled risk ratio of 2.51 (95% CI,
1.79–3.54).9 Our observations of doubled risk are in line with
these earlier reports, adding weight to the association between
SSc and venous thromboembolism. The mechanistic link,
however, cannot be determined from our study. It is possible
that although the prevalence of rheumatoid arthritis, systemic
lupus erythematosus, and mixed connective tissue disorders
was small (<5%) in our study cohort, some of the observed
association between SSc and venous thromboembolism (and
potentially other cardiovascular disorders) was driven by the
presence of these and other autoimmune comorbidities.
Study Strengths and Weaknesses
Danish registries are considered accurate and complete and
can contribute to the study of rare diseases.61 Because
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almost all patients in Denmark with SSc are followed in
specialized departments of rheumatology or dermatology,
selection and recall bias as a source of error is low given
the nationwide administrative setup. However, a detection
bias of cardiovascular diseases may have occurred in the
SSc cohort because of the regular specialized care and
surveillance (eg, valvular diseases may have been detected
because of more frequent echocardiography). Bias could
also be introduced if SSc patients had diagnoses coded
more often than controls because of a more thorough
coding practice by their treating physicians. However,
because of the Danish reimbursement policy, physicians
should code only clinically significant conditions of impor-
tance to the specific contact (eg, valve disorders should be
coded only if they require follow-up), making such bias less
likely. Our observations were also strengthened by genetic
evidence suggesting a causal relationship between SSc and
many of the cardiovascular manifestations, underscoring
that surveillance and coding practices might not be solely
responsible for the observed associations. The main
strength of the study includes the high number of cases
and the long duration of follow-up. Considering the high
validity in the National Patient Registry of the exposure and
outcome variables used in this study,15–17,19 the potential
for inaccurate diagnosis and consequently misleading
calculations should be low; however, it should be acknowl-
edged that a few diagnoses (eg, pulmonary hypertension)
have never been validated. Furthermore, the diagnoses
could not be used to subclassify the disease severity (eg,
severity of an aortic stenosis). In the multivariable analysis,
several end points had a relatively low number of incident
cases, and the rule of thumb that the number of events
should be at least 10 times the number of covariates was
not met for all end points. Therefore, caution is advised
when interpreting the results from the multivariable anal-
ysis. Of note, our study spans a time period in which the
classification criteria of SSc have evolved,62–64 and the
increasing use of serological markers and capillaroscopy,
for example, have yielded increases in the number of
patients fulfilling disease criteria.65–67 It is likely that our
cohort contained a larger proportion of early and mild
disease compared with earlier cohorts, although we did not
have information allowing us to differentiate distinct
phenotypes of SSc with regard to extent of skin involve-
ment or serological features known to be associated with
mortality in SSc.68 Moreover, residual confounding cannot
be refuted because valid information on lifestyle parameters
(eg, tobacco, alcohol, body mass index, physical activity
level) is not available in the registries used for this study.
Our cohort was based on a homogeneous ethnic northern
European population, making extrapolation to other ethnic-
ities difficult.
Conclusions
The magnitude of cardiovascular manifestations estimated in
our study suggests a significant disease-related adverse
impact across the vascular bed and specific cardiac
structures, warranting an increased focus on less recognized
complications. The limited understanding of the pathology
and dynamics behind our multifaceted findings reflects an
unmet need for characterization of key determinants of risk
and causal factors of cardiovascular complications in SSc.
Our findings require more research; however, our study
supports a multidisciplinary approach for the assessment
of cardiovascular disease and its treatment in patients with
SSc.
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Supplemental Methods 
 
For the present study we cross-linked the Central Population Registry (using individual-level data) 
with the National Patient Registry and the National Prescription Registry. The Central Population 
Registry contains the unique personal identification numbers of all Danish residents along with 
information on their birthdate, gender, and vital status. The National Patient Registry contains 
information on all in- and out-hospital diagnoses, registered according to the International 
Classification of Diseases (ICD) system; revision 8 in 1978-1993 and the 10th revision since 1994. 
The accuracy and completeness of diagnostic coding in the National Patient Registry has been 
evaluated as consistently high for a variety of chronic comorbidities and cardiovascular diagnoses 1-
4, and we have previously found a positive predictive value of 94% for the SSc diagnosis in this 
registry.5 The National Prescription Registry holds information on all prescription claims since 
1995 with all drugs being classified according to the Anatomical Therapeutical Chemical 
classification system. Due to the reimbursement-driven policy, this registry is considered of high 
quality.6 
 
Study population   
In the National Patient Registry, we identified all first-time diagnoses of SSc (ICD-10 codes M34 
[except for M34.2]) that followed outpatient or inpatient visits between 1995 and 2015. We 
excluded patients with a prior diagnosis of SSc defined as an ICD-10 code of M34 in 1994 or an 
ICD-8 code of 734 anytime between 1978 and 1993. The controls consisted of five randomly 
selected age- and sex-matched individuals from the Central Population Registry. An index date was 
assigned to each control, which corresponded with the date of first registration of SSc for their 
respective case, in accordance with the principle of incidence density sampling.7  
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Outcome variables and follow up 
The primary outcome variables were defined by ICD-8 and ICD-10 codes, together with procedural 
codes (obtained via the National Patient Registry) and medication use (obtained via the Anatomical 
Therapeutic Chemical (ATC) Classification System coding in the National Prescription Registry).  
Supplemental Table S1 shows the different variables, different registries, and the corresponding 
diagnosis or procedure/surgical codes for each outcome.   
 
Comorbidity and Medications 
Baseline comorbidity was assessed as a prevalent condition at any time before study inclusion. 
Comorbidity included hypertension, atrial fibrillation, heart failure of any cause, myocardial 
infarction, ischemic stroke, aortic aneurism and dissection, aortic stenosis and regurgitation, mitral 
stenosis and regurgitation, conduction block (left bundle branch block and atrioventricular block), 
implantation of pacemaker or implantable cardioverter defibrillator, pericarditis, peripheral vascular 
disease, pulmonary hypertension, venous thromboembolism, treated dyslipidemia, and diabetes. 
Baseline treatment was defined by at least one prescription dispensed for each respective drug up to 
180 days before the study inclusion date. The following drugs were included: aspirin, nonsteroidal 
anti-inflammatory drugs, statins, oral anticoagulants, anti-platelet therapy and glucocorticoids.  
 
Statistics 
Continuous variables are presented as mean with standard deviation, categorical variables as 
absolute number and percentages. Tests for differences between groups were performed by the 
Pearson’s Chi-squared/Fischer’s exact test (categorical data) or by the Student t test (continuous 
data) where appropriate. Time at risk was measured from index date (date of SSc diagnosis) and 
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individuals were censored at the date of first-time registration of the specific endpoint, migration or 
upon death. Conditional logistic regression models and Cox proportional hazards regression models 
were used to calculate the odds ratios (OR) for prevalent cardiovascular diseases and hazard ratios 
(HR) for incident diseases associated with SSc, respectively. Separate models were run for each 
endpoint. The main models were adjusted for age and sex. In addition, a multivariable Cox 
regression model (including all comorbidities and treatment in Table 1) was applied to investigate 
the association of SSc and outcomes after adjustment for various comorbidities and risk factors. 
Two-sided p-values <0.05 were considered statistically significant for all analyses. All analyses 
were performed in SAS version 9.4 (Cary, NC, USA).  
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Table S1. Variables and sources. Diagnoses (ICD-8 and ICD-10) and medication (ATC) codes 
used. 
 
Disease/condition Definition (Register) Variables 
Hypertension 
 
ATC (National Prescription 
Registry) 
ATC: C02A, C02B, C02C, C02DA, 
C02DB, C02DD, C02DG, C02L, C03A, 
C03B, C03D, C03E, C03X, C04, C05, 
C07A, C07B, C07C, C07D, C07F, C08, 
C08G, C09AA, C09BA, C09BB, C09CA, 
C09DA, C09DB, C09XA02, C09CA52 
Ischemic stroke 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 433,  
ICD-10 I63-64 
Acute myocardial infarction  
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 410,  
ICD-10 I21-22 
Ischemic heart disease 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 410-414, 
 ICD-10 I20-25 
Heart failure ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 425, 4270-1,  
ICD-10 I42, I50, I110 
Aortic aneurism (abdominal or 
thoracic) 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 441,  
ICD-10 I711-I719 
Aortic dissection (abdominal or 
thoracic) 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-10 I71.0 
Aortic stenosis 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-10 I35.0, I35.2 
Aortic regurgitation 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-10 I34.0, I34.1 
Mitral valve stenosis 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-10 I34.2 
Mitral valve regurgitation or 
prolapse 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-10 I34.0-I34.1 
Atrial fibrillation 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 4274,  
ICD-10 I48 
Conduction block (left bundle 
branch or atrioventricular block)  
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 4273,  
ICD-10 I44 
Pericarditis 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 420, 421,  
ICD-10 I30-I32 
Peripheral artery disease 
and atherosclerosis in aorta 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 440,  
ICD-10 I70, I74 
Pulmonary hypertension 
 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 426,  
ICD-10 I27 
Deep venous thrombosis or 
pulmonary embolism 
ICD8 or ICD10 diagnostic codes 
(National Patient Registry) 
ICD-8 450, 451,  
ICD-10 I26, I80, I82 (excl. I80.0, I80.8, 
I82.0) 
D
ow
nloaded from
 http://ahajournals.org by on A
ugust 27, 2019
Cardiac pacemaker 
Procedure and surgical code 
(National Patient Registry) 
BFCA0, BFCA6, KFPE00, KFPE10, 
KFPE20, KFPE96, KFPF00, KFPF10, 
KFPF20, KFPF96 
Implantable Cardioverter 
Defibrillator 
Procedure and surgical code 
(National Patient Registry) 
BFCB0, BFCB6, KFPG  
 
Diabetes 
ATC (National Prescription 
Registry) 
ATC: A10 
Aspirin 
ATC (National Prescription 
Registry) 
B01AC06  
NSAID (nonsteroidal anti-
inflammatory drugs) 
ATC (National Prescription 
Registry) 
M01A 
Treated dyslipidemia 
ATC (National Prescription 
Registry) 
C10AA 
OAC (oral anticoagulant) 
ATC (National Prescription 
Registry) 
B01 
Anti-platelet therapy 
ATC (National Prescription 
Registry) 
B01AC 
Glucocorticoids 
ATC (National Prescription 
Registry) 
H02AB 
 
 
Hypertension was defined by use of at least 2 antihypertensive drugs according to a validated 
algorithm4, diabetes was defined by use of a glucose-lowering drug while treated dyslipidemia 
was defined as the use of statins. ATC; anatomical therapeutic chemical classification system. 
ICD-10; International Classification of Diseases 10th revision. 
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Table S2. Hazard ratio (HR) and 95% confidence interval (CI) for incident disease (fully 
adjusted model). 
Outcome HR 
Hypertension 1.90 (1.76-2.05) 
Atrial fibrillation 1.57 (1.33-1.86) 
Heart failure 2.43 (2.02-2.91) 
Myocardial infarction 1.91 (1.47-2.47) 
Ischemic stroke 1.13 (0.90-1.42) 
Aortic aneurism 1.18 (0.70-2.07) 
Aortic dissection NA 
Aortic stenosis 2.85 (2.07-3.93) 
Aortic regurgitation 2.49 (1.56-3.97) 
Mitral stenosis NA 
Mitral regurgitation 4.43 (2.75-7.12) 
Conduction block (LBBB/AVB) 1.59 (1.00-2.55) 
Pacemaker/Implantable cardioverter defibrillator 1.63 (1.12-2.37) 
Pericarditis  8.31 (3.74-18.46) 
Peripheral vascular disease 5.54 (4.37-7.02) 
Pulmonary hypertension 21.06 (13.78-32.19) 
Venous thromboembolism 1.92 (1.48-2.49) 
Diabetes 0.93 (0.75-1.15) 
 
Fully adjusted HR was adjusted for medications (ASA, NSAID, Glucocorticoids, statins, OAC and 
platelet inhibitors) and co-morbidities, as specified in Table 1. 
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Table S3. Associations of rs3894194 and rs4134466 with cardiovascular phenotypes at p<0.10 
from the UK Biobank based gene atlas.  
 
 
Data obtained from pheWAS summary results statistics at http://geneatlas.roslin.ed.ac.uk/phewas/, 
accessed March 27, 2019.8  
 
 
Variant Eff. Allele Trait Beta p-value 
rs3894194, odds ratio 0.85 (0.81 to 0.90), p=6.6e-10 in original GWAS of systemic 
sclerosis  
rs3894194 G 
I70-I79 Diseases of arteries, arterioles and 
capillaries -0.00091 0.0011 
rs3894194 G I50 Heart failure -0.00072 0.0026 
rs3894194 G I30-I52 Other forms of heart disease -0.0015 0.0046 
rs3894194 G I77 Other disorders of arteries and arterioles -0.00032 0.0095 
rs3894194 G I74 Arterial embolism and thrombosis -0.00024 0.018 
rs3894194 G I21 Acute myocardial infarction -0.00066 0.020 
rs3894194 G Essential hypertension 0.00028 0.043 
rs3894194 G Heart attack/myocardial infarction -0.00061 0.045 
rs3894194 G I73 Other peripheral vascular diseases -0.00039 0.051 
rs3894194 G I34 Nonrheumatic mitral valve disorders -0.00030 0.058 
rs3894194 G I71 Aortic aneurysm and dissection -0.00023 0.059 
rs3894194 G I95 Hypotension -0.00041 0.069 
rs3894194 G I72 Other aneurysm -0.00013 0.072 
rs3894194 G K55 Vascular disorders of intestine 0.00018 0.080 
     
rs4134466, odds ratio 0.85 (0.80 to 0.89), p=1.4e−10 in original GWAS of systemic 
sclerosis  
rs4134466 G I70 Atherosclerosis -0.00035 0.0033 
rs4134466 G I72 Other aneurysm -0.00019 0.0075 
rs4134466 G 
I70-I79 Diseases of arteries, arterioles and 
capillaries -0.00074 0.0090 
rs4134466 G Peripheral vascular disease -0.00028 0.015 
rs4134466 G Heart arrhythmia -0.00052 0.044 
rs4134466 G I61 Intracerebral haemorrhage -0.00017 0.050 
rs4134466 G 
I51 Complications and ill-defined descriptions 
of heart disease -0.00040 0.059 
rs4134466 G I30-I52 Other forms of heart disease -0.00095 0.069 
rs4134466 G heart attack/myocardial infarction -0.00056 0.072 
rs4134466 G I47 Paroxysmal tachycardia 0.00033 0.082 
rs4134466 G I45 Other conduction disorders -0.00026 0.094 
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